Multiple sclerosis

MS · Neurology · 4 drugs · 5 indications

Autoimmune demyelinating disease of CNS. Includes relapsing and progressive forms.

Competitive Landscape (4 drugs)

Drug	Company	Mechanism	Modality	Route	Stage
Fenebrutinib	ROG.SW	BTK inhibitor	BTK inhibitor	Oral	PHASE3
Ocrevus	ROG.SW	CD20 antagonist	Antibody	IV	APPROVED
Kesimpta	NVS, GMAB	CD20 antagonist	Antibody	SC	APPROVED
Mayzent	NVS	S1P receptor modulator	Small molecule	Oral	APPROVED

Indications (5)

Relapsing Multiple Sclerosis

Primary Progressive MS

SPMS

Mayzent APPROVED

RMS

Mayzent APPROVED

Relapsing forms of multiple sclerosis

Kesimpta APPROVED

Upcoming Catalysts

Fenebrutinib - RMS - Ph3 - Topline (FENhance 1)CLINICAL

ROG.SWH1 2026

Data from Supabase · Updated 2026-03-24